Latest Conference Articles

DESTINY-Breast05 analyses show post neoadjuvant Enhertu improves invasive disease free survival compared with Kadcyla in patients with residual early stage breast cancer.

Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower.

Inluriyo and Verzenio helped patients with ER+/HER2– advanced breast cancer stay on treatment longer without their disease worsening vs standard therapy.

Hormone therapy after breast cancer did not increase risk in BRCA1/2 carriers; estrogen alone was linked to lower risk.

For AYA breast cancer survivors, mobile health intervention was associated with improvements to general and cancer-specific quality of life.

Real and sham acupuncture improved perceived cognitive function versus usual care, with real acupuncture showing greater benefits for objective cognitive outcomes.

Emmy-winning journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration.

CURE spoke with Dr. Dickran Kazandjian about why MRD matters for patients with multiple myeloma.

The 60-month local regional recurrence-free rate was 93.2% in the MRI arm versus 95.7% in the no MRI arm, researchers reported.

Adding radiation before surgery with Keytruda increased immune cells in tumors and led to encouraging responses in people with early-stage breast cancer.

Tecentriq numerically increased the rates of chemotherapy-induced ovarian failure compared with chemotherapy alone for patients with triple-negative breast cancer.

Verzenio showed meaningful improvement for some patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 treatment.

Nuvisertib plus momelotinib is safe and generated improvements in symptom burden, spleen volume, and anemia outcomes in relapsed/refractory myelofibrosis.

Giredestrant generated improved outcomes over standard endocrine therapy in patients with ER+/HER2–, medium- and high-risk early breast cancer.

Progression-free survival was not statistically significant with Trodelvy versus chemotherapy as first-line treatment in HR+/HER2– metastatic breast cancer.

Emmy-winning journalist and author, Suleika Jaouad, delivered the keynote address at the inaugural Blood Cancer Heroes event.

KLN-1010 was associated with deep, ongoing minimal residual disease (MRD)–negative responses in multiple myeloma.

Real-world treatment with Yescarta demonstrated durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Dexamethasone before Yescarta reduced the severity of ICANS but did not change how often ICANS or CRS occurred in patients with LBCL.

Pelabresib plus Jakafi delivered stronger, clinically meaningful benefits versus Jakafi alone for people with untreated myelofibrosis.

Tecvayli plus Darzalex Faspro improved overall and progression-free survival versus standard daratumumab regimens in relapsed/refractory multiple myeloma.

Jaypirca therapy improved progression-free survival versus bendamustine plus Rituxan a phase 3 trial for untreated CLL/SLL.

Lore Gruenbaum, chief scientific officer of Blood Cancer United, sat down for an interview with CURE to discuss the themes shaping blood cancer care today.

Dr. Robert Orlowski says a single-drug option in newly diagnosed myeloma may offer strong responses with fewer side effects and preserve future treatments.

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.

The phase 3 EPCORE FL-1 trial showed that adding Epkinly to Rituxan and Revlimid delivered superior PFS and response rates.

A new combination of Blincyto and Iclusig provided improved results and stronger responses for patients with Philadelphia chromosome-positive ALL compared with traditional chemotherapy.

Among fit patients with acute myeloid leukemia, azacitidine plus Venclexta was shown to be superior to intensive chemotherapy.